In adults with type 2 diabetes, retatrutide lowered A1C by an average of 2.2% vs ... At 80 weeks, retatrutide met the primary and all key secondary endpoints, delivering greater A1C reduction and substantially more weight loss than Ozempic.1,2.
In ACHIEVE-4, participants taking Foundayo experienced a 16% lower risk of MACE-4 and a 23% lower risk of MACE-3, meeting the primary objective for non-inferiority compared to insulin glargine ....
In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks, with more than half no longer meeting the BMI criteria for obesity ... .
Participants taking EloraTZP lowered their A1C by up to an average of 2.9% compared to 2.4% with tirzepatide 15 mg ... delivering substantial weight loss and A1C reduction ... Change in A1C from an avg.
Change in A1C frommean baseline of8.22% at 52 Weeks iii ... Percent of participants achieving A1C ≤6.5%iii, iv ... iiiResults of A1C and body weight were based on efficacy estimand.3.
Foundayo 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg at 52 weeks ... Additionally, Foundayo lowered A1C by 0.3% more than oral semaglutide 25 mg (95% CI -0.6%, -0.1%).
Retatrutide reduced A1C by up to an average of 1.6%, with up to 40.0% reaching an A1C of <5.7% ...Beyond substantially reducing weight, retatrutide also helped participants better control their A1C ... Change in A1C from ... achieving A1C ... achieving A1C.